Abstract
Clinical global impressions of change (CGICs) are important measures of efficacy in clinical trials. CGIC scales have been used extensively as primary outcome criteria in psychopharmacological trials and in early clinical trials for antidementia drugs (e.g., Schneider and Olin, 1994). CGICs have been reported to be the most sensitive index of change in 14 of 17 dementia trials, when compared to other measures (Lehmann, 1984).
Keywords
- Global Rating
- Clinical Global Impression
- Clinical Dementia Rate
- Clinical Global Impression
- Global Deterioration Scale
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Clinical Global Impressions (CGI) (1976): In: ECDEU Assessment Manual for Psychopharmacology, Guy W, ed. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, pp. 218–222.
Folstein MF, Folstein SE, McHugh PR (1975): “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J Psyehiatr Res 12:189–198.
Leber P. (November, 1991): Unpublished letter to pharmaceutical companies [Issues affecting the implementation of the Clinician’s Global Assessment].
Lehmann E (1984): Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales. Pharmacopsyehiat 17:71–75.
McKhann G, Drachman D, Folstein M, et al. (1984): Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944.
Morris JC (1993): The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43:2412–2414.
Olin JT, Clark C, Doody R, Schmitt F, Ferris S, Morris J, Reisberg B, Schneider LS (1996): Reliability and validity of a new clinical global rating scale for Alzheimer’s clinical trials. J Int Neuropsychol Soc 2:4
Reisberg B (1988): Functional assessment staging (FAST). Psyehopharmaeol Bull 24:653–659.
Reisberg B, Ferris SH, deLeon MJ, Crook T (1982): The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139:1136–1139.
Schneider LS, Olin JT (1994): Quantitative overview of the efficacy of Hydergine. Arch Neurol 51:787–798.
Schneider LS, Olin JT (1996): Clinical Global Impressions in Clinical Trials. Int. Psychogeriat (In Press)
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH (1996): Validity and reliability of the Alzheimer’s Disease Study-Clinical Global Impression of Change (ADCS-CGIC). Alzheimer’s Disease and Associated Disorders. (In Press,)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Birkhäuser Boston
About this chapter
Cite this chapter
Schneider, L.S. et al. (1997). Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). In: Becker, R.E., Giacobini, E., Barton, J.M., Brown, M. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4116-4_64
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4116-4_64
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8660-8
Online ISBN: 978-1-4612-4116-4
eBook Packages: Springer Book Archive